Akums Drugs & Pharmaceuticals Ltd's Q2 FY27 numbers came in strong, with revenue of Rs. 1,342.39 Cr (+31.93% YoY) and PAT growth of +168.33% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | November 02, 2026 |
|---|---|
| Revenue (Q2) | Rs. 1,342.39 Cr (+31.93% YoY) |
| PAT (Q2) | Rs. 114.57 Cr (+168.33% YoY) |
| EBITDA margin | 14.51% (+523 bps YoY) |
| EPS (Q2) | Rs. 7.37 (+177.07% YoY) |
Akums delivered 31.93% YoY revenue growth with EBITDA margin of 14.51% within management's 14-15% FY27 band, and PAT up 168.33% YoY on broad operating leverage. Watch items are the API segment's continued EBITDA-negative run (contradicting the Q1 claim), QoQ margin slippage off the upper guidance bracket, and the open Rs.156.02 Cr IT and Rs.52.75 Cr NPPA demands. The balance sheet remains substantially net-cash while funding capex, the Oriflame acquisition, and dividends without new borrowings.
| Driver | Expected before results | What happened | Verdict |
|---|---|---|---|
| Revenue | "likely ahead" on IPM value momentum + FDA approval flow | Revenue +31.93% YoY, +15.07% QoQ | Played out |
| EBITDA margin | "test whether the 15.0% Q1 print holds within the 14–15% band rather than expands" | 14.51% — in band, slipped from upper bracket | Partially |
| Power & fuel | "an unambiguous headwind to other expenses" | Other expenses +10.94% YoY vs revenue +31.93%; ratio down to 11.67% from 13.88% — leverage overwhelmed it | Contradicted |
| API prices | "two-sided/unresolved; company's volatility flag operative" | API segment EBITDA-negative and wider QoQ (−Rs.5.74 Cr) — risk visible | Played out |
| FX | "~1% rupee depreciation = conversion tailwind for export CDMO" | International branded +95.12% YoY; FX attribution not disclosed in filing | Partially |
| NPPA demand | "could surface as provisioning/exceptional treatment" | No provision, no exceptional; disclosure-only — remains open | Not observable as a Q2 P&L item |
| Watch: Zambia supplies by end-Q2 | confirmation sought | Not addressed in the filing — open for the call | Not observable |
| Watch: notional EU-advance interest cessation | watch for cessation | Still running — Rs.20.22 Cr unwind in Q2 finance costs | Confirmed continuing |
Read our full results preview.
| What management said | Where | What happened | Verdict |
|---|---|---|---|
| EBITDA margin 14–15% FY27, "inclined towards the upper bracket" | Q1 FY27 earnings call (management: "we have always guided for a 14% to 15% margin... given q1 has been strong, we can incline towards the upper bracket of it") | 14.51% (management definition, consolidated) — within band, but off the upper bracket vs Q1's 14.97% | Met |
| API segment monthly EBITDA positive by end-Feb/Mar 2027 | Q1 FY27 earnings call | Segment results before depreciation −Rs.5.74 Cr (negative; wider than Q1's −Rs.3.90 Cr) | Too Early on the stated timeline, but the sign is still negative |
| Capex Rs.300 Cr FY27 | Q4 FY26 earnings call | H1 spend Rs.154.21 Cr (~51%) | On Track |
| Trade generics sustain EBITDA positivity | management commentary, Q4 FY26 (turned positive "as targeted") | +Rs.1.19 Cr before depreciation / +Rs.1.13 Cr after | Met |
| ETR normalise toward 25% | management commentary (open-ended) | 25.96% this quarter (from 34.99% YoY) | Met this quarter |
| Base CDMO margins 15–16% by FY28 | prior earnings-call guidance | 14.39% before depreciation this quarter | Too Early |
| "API segment became EBITDA positive" on a higher non-cepha share | Q1 FY27 MD message | Filed segment tables show API negative in both Q1 (−Rs.3.90 Cr) and Q2 (−Rs.5.74 Cr) before depreciation | Contradicted |
| Volume-led, market-outperforming growth (high-teens volume) | Q1 FY27 call / MD message | Revenue +31.93% YoY with all cost lines leveraged; volume itself is not disclosed in the filing | Confirmed in revenue terms; volume quantum not disclosed |
| Strong cash position funding growth and acquisitions | prior calls / MD message | Rs.1,680 Cr liquid, borrowings Rs.36.15 Cr, funded Rs.154.21 Cr capex + Rs.56.00 Cr acquisition + Rs.45.92 Cr dividend without net borrowing | Confirmed |
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.